With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Blocking the Evil Messenger in MYCN-driven High-risk Neuroblastoma||Boston University / Hui Feng, Md, PhD||Innovation Grants||2022||Massachusetts|
|Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma||University of California San Francisco / William Clay Gustafson, MD, PhD||'A' Award Grants||2011||California|
|Blockade of MYCN in neuroblastoma||University of California San Francisco / William Weiss, MD/PhD||Innovation Grants||2011||California|
|Blockade of Mycn in neuroblastoma||University of California San Francisco / William Weiss||Innovation Grants||2008||California|
|Biology-based clinical trials for children with cancer.||Children’s Hospital of Philadelphia / Rochelle Bagatell||Phase I/II Infrastructure Grants||2009||Pennsylvania|
|BH3 profiling to define therapy resistance classes in neuroblastoma.||Children’s Hospital of Philadelphia / Michael Hogarty||Innovation Grants||2009||Pennsylvania|
|BH3 Profiling to define therapy resistance classes in neuroblastoma||Children’s Hospital of Philadelphia / Michael Hogarty, MD||Innovation Grants||2011||Pennsylvania|
|Beyond Febrile Neutropenia: Risks Associated with Antibiotic Choice in Children with Leukemia that Undergo Transplant||Children’s Hospital of Philadelphia / Caitlin Elgarten, MD||Young Investigator Grants||2018||Pennsylvania|
|BET Bromodomain Inhibition as Epigenetic Therapy in Pediatric Leukemia||Cold Spring Harbor Laboratory / Christopher Vakoc, MD, PhD||'A' Award Grants||2012||New York|
|Bcl2-Family Inhibitors in Neuroblastoma: Mechanism of Action, Therapy Resistance, and Development of Biomarkers||Children’s Hospital of Philadelphia / Claudia Zapata, MD||Young Investigator Grants||2019||Pennsylvania|